http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
구자성 대한뇌졸중학회 2010 Journal of stroke Vol.12 No.3
Antiplatelet drugs are widely used for prevention and treatment of ischemic stroke and transient ischemic attack. Considering the limited efficacy of antiplatelet drugs, combination of antiplatelet drugs can be used to potentiate antiplatelet effect. Compared to aspirin or clopidogrel alone, the combination of aspirin and clopidogrel increased the risk of bleeding complication without any additional benefit. In patients who had nonvalvular atrial fibrillation and were ineligible for oral anticoagulant, the combination aspirin and clopidogrel was better than aspirin alone though the risk of bleeding increased significantly. In two large clinical studies, the combination of aspirin and extended-release dipyridamole was more effective than aspirin alone without increasing bleeding complication. However the result of comparison to clopidogrel alone was disappointing. The combination of aspirin and cilostazol might be better than aspirin alone in preventing the progression of symptomatic stenosis of intracranial artery. Further studies are needed to investigate the risk and benefit of the combination of antiplatelet drugs in selected group of patients with acute ischemic stroke or large artery atherosclerotic stroke. (Korean J Stroke 2010;12:88-95)
한국뇌졸중진료지침에서 아스피린의 뇌졸중 일차예방효과에 관한 내용의 부분개정
구자성,한상원,김한영,박종무,조용진,강규식,유경호,나정호,허지회,권순억,오창완,배희준,이병철,윤병우,홍근식 대한신경과학회 2011 대한신경과학회지 Vol.29 No.4
The first edition of the Korean clinical practice guidelines for primary stroke prevention reflects evidence published before June 2007. Since then, several clinical studies and meta-analyses have been conducted to determine the efficacy of aspirin for the primary prevention of cardiovascular disease including stroke. The aim of this guideline update is to provide timely recommendations taking into consideration the new evidence. Three clinical studies and four meta-analyses performed between July 2007 and November 2010 were identified and included for updating the guidelines. The main finding was a lack of aspirin efficacy for primary stroke prevention in patients with diabetes or peripheral arterial disease. We have summarized the new evidence and revised our recommendations for aspirin for primary stroke prevention. New evidence will need to be reflected continuously in future guideline updates.